Biopharmaceutical company Insmed Inc. said Oct. 24 that it has earned the highest ranking in Science magazine’s 2025 Top Employers Survey.
The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the companies with the best reputations as employers. This is the fifth consecutive year Insmed has been recognized by the publication.
“It is an incredible privilege to see our organization recognized as the top employer in Science’s annual survey for a record five consecutive years — something only achieved once before when the list first began,” said Will Lewis, chair and chief executive officer of Insmed.
“We are experiencing an extraordinary period of growth, driven by a series of clinical successes and regulatory milestones that support us in working toward our mission to transform the lives of patients with serious and rare diseases. This recognition reflects not only our deep commitment to advancing science, but also the passion and purpose that drive our work every day.”
The 2025 survey results were based on about 5,500 responses from individuals located across North America (66%), Europe (20%), and Asia/Pacific Rim (9%). This year’s highest-ranking companies stood out in the areas of corporate image, financial prowess, leadership and direction, work culture and environment, and academic and intellectual challenge.
“Being recognized once again by Science as the top employer in the biopharma industry is a tremendous honor and a reflection of the people-first culture we continue to build at Insmed,” said Nicole Schaeffer, chief people strategy officer of Insmed.
“By fostering an environment where collaboration meets flexibility, we enable our talented team to drive scientific breakthroughs on behalf of patients with serious diseases. I’m grateful to every colleague who makes Insmed such a special place to work.”
Insmed is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines. Its most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases.
In August, the Food and Drug Administration approved Insmed’s oral drug for a type of lung disease, making it the first treatment for the chronic condition. Insmed’s drug, branded as Brinsupri, targets non-cystic fibrosis bronchiectasis, a chronic lung condition characterized by permanently damaged airways, leading to persistent cough and excessive mucus production.
Insmed has a market cap of $33.91 billion and its shares this year have risen 132.4% to $160.43 on the NASDAQ Global Select Market Composite.
Based in Bridgewater, Insmed has more than 1,500 employees in offices and research locations throughout the United States, Europe, and Japan.
